Data regarding an innovative bispecific antibody – CPL-976 (CPBT-0976) – were recently reported by Celon Pharma SA. Bispecific antibodies targeting more than one antigen on cancer cells improve the specificity and effectiveness of the therapy, and could be utilized for targeting the defense mechanisms of cancer cells, such PD-L1 or EGFR, VEGFR and AXL.
Caribou Biosciences Inc. has received FDA clearance of its IND application for CB-012, an allogeneic anti-C-type lectin-like molecule-1 (anti-CLL-1) chimeric antigen receptor (CAR) T-cell therapy. CLL-1 is highly expressed on acute myeloid leukemia (AML) cells and leukemic stem cells, but it is not expressed on hematopoietic stem cells.
Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform.
Cimeio Therapeutics Inc. has entered into a preclinical research collaboration with a researcher at the University of Pennsylvania (Penn) to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers.
In recent years, the introduction of immune checkpoint inhibitors to the oncolytic pipeline has been a significant breakthrough in cancer treatment, but unfortunately some tumors respond only minimally. Besides CTLA-4, and since the approval of PD-1/PD-L1 inhibitors, only the anti-LAG3 strategy (relatlimab, Bristol Myers Squibb Co.) has been good enough to reach the market. In a session dealing with emerging checkpoints beyond PD-1, CTLA-4 and LAG3, Drew Rasco from the START Center for Cancer Care depicted a new player on the ground of immunotherapeutic options.
Duality Biologics (Suzhou) Co. Ltd. has synthesized antibody-drug conjugates comprising anti-GPC3 antibodies covalently linked to exatecan derivatives through a linker. They are reported to be useful for the treatment of cancer.
Sotio Biotech AS, a company owned by PPF Group, has entered into a license and option agreement with Synaffix BV, a Lonza company, to develop next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors.
Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a strategic research collaboration and worldwide license agreement with Biontech SE for the development of a next-generation antibody-drug conjugate candidate (ADC) against HER3.
RSS
